Biogen/Elan Antegren Crohn’s Plans Await Talks With FDA After Trial Fails
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
The need for additional studies for Biogen/Elan’s Antegren in Crohn’s disease could hinge upon FDA’s acceptance of data from secondary endpoints or subgroup analysis of the ENACT-1 pivotal trial.